KR20250005125A - NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체 - Google Patents

NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체 Download PDF

Info

Publication number
KR20250005125A
KR20250005125A KR1020247034096A KR20247034096A KR20250005125A KR 20250005125 A KR20250005125 A KR 20250005125A KR 1020247034096 A KR1020247034096 A KR 1020247034096A KR 20247034096 A KR20247034096 A KR 20247034096A KR 20250005125 A KR20250005125 A KR 20250005125A
Authority
KR
South Korea
Prior art keywords
compound
disease
pharmaceutically acceptable
acceptable salt
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247034096A
Other languages
English (en)
Korean (ko)
Inventor
스테판 도리치
아만딘 셰프손
스테판 시블라트
Original Assignee
벤투스 테라퓨틱스 유에스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/704,983 external-priority patent/US11618751B1/en
Application filed by 벤투스 테라퓨틱스 유에스 인코포레이티드 filed Critical 벤투스 테라퓨틱스 유에스 인코포레이티드
Publication of KR20250005125A publication Critical patent/KR20250005125A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020247034096A 2022-03-25 2023-03-24 NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체 Pending KR20250005125A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17/704,983 US11618751B1 (en) 2022-03-25 2022-03-25 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US17/704,983 2022-03-25
US202263420930P 2022-10-31 2022-10-31
US63/420,930 2022-10-31
US202363443874P 2023-02-07 2023-02-07
US63/443,874 2023-02-07
PCT/US2023/064967 WO2023183943A1 (en) 2022-03-25 2023-03-24 Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives

Publications (1)

Publication Number Publication Date
KR20250005125A true KR20250005125A (ko) 2025-01-09

Family

ID=86329581

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034096A Pending KR20250005125A (ko) 2022-03-25 2023-03-24 NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체

Country Status (13)

Country Link
EP (1) EP4499638A1 (https=)
JP (1) JP2025510414A (https=)
KR (1) KR20250005125A (https=)
CN (1) CN119137121A (https=)
AU (1) AU2023238121A1 (https=)
CA (1) CA3246681A1 (https=)
CL (1) CL2024002855A1 (https=)
CO (1) CO2024013702A2 (https=)
IL (1) IL315842A (https=)
MX (1) MX2024011697A (https=)
PE (1) PE20250605A1 (https=)
TW (1) TW202345836A (https=)
WO (1) WO2023183943A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
TW202313577A (zh) 2021-06-04 2023-04-01 瑞士商赫孚孟拉羅股份公司 新穎化合物
US12331048B2 (en) * 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
KR20250106322A (ko) * 2022-12-28 2025-07-09 장춘 진사이언스 파마슈티컬 씨오., 엘티디. 피리다진계 nlrp3 억제제 화합물, 약학 조성물 및 이의 제조 방법과 용도
WO2025059481A1 (en) 2023-09-13 2025-03-20 Ventus Therapeutics U.S., Inc. Solid forms of an nlrp3 inhibitor and uses thereof
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11618751B1 (en) * 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CR20240093A (es) * 2021-08-25 2024-05-23 Ptc Therapeutics Inc Inhibidores de NLRP3

Also Published As

Publication number Publication date
MX2024011697A (es) 2024-11-08
JP2025510414A (ja) 2025-04-14
IL315842A (en) 2024-11-01
PE20250605A1 (es) 2025-02-26
CA3246681A1 (en) 2023-09-28
CN119137121A (zh) 2024-12-13
WO2023183943A1 (en) 2023-09-28
TW202345836A (zh) 2023-12-01
CO2024013702A2 (es) 2024-11-08
CL2024002855A1 (es) 2025-02-14
AU2023238121A1 (en) 2024-10-10
EP4499638A1 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
EP4320102B1 (en) Pyridazine compounds for inhibiting nlrp3
KR20250005125A (ko) NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체
US12312351B2 (en) Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
US20240368131A1 (en) Oxoindolinyl amide derivatives for inhibiting nlrp3 and uses thereof
HK40100030A (en) Compounds for inhibiting nlrp3 and uses thereof
KR20230157535A (ko) Nlrp3을 저해하기 위한 피리다진 화합물
EA051595B1 (ru) Соединения пиридазина для ингибирования nlrp3

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000